Pfenex Announces U.S. Commercial Launch of Teriparatide Injection
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Pfenex Inc. (PFNX) PT Raised to $15 at Oppenheimer
June 15, 2020 9:19 AM EDTOppenheimer analyst Francois Brisebois raised the price target on Pfenex Inc. (NYSE: PFNX) to $15.00 (from $10.00) while maintaining a Outperform rating following the company's announcement that its commercial partner Alvogen opted to proceed with the US launch of PF708 to increase bone density in... More
